BioCryst Pharmaceuticals (BCRX) News Today $6.81 +0.39 (+6.07%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$6.82 +0.01 (+0.16%) As of 10/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is BioCryst Pharmaceuticals Up Today?Toggle Visibility of Why Is BioCryst Pharmaceuticals Up Today?BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) — Shares are trading higher after a flurry of analyst upgrades and price-target increases, alongside BioCryst’s announced acquisition of Astria Therapeutics (navenibart). Investors are reacting to both the strategic growth case and short‑term financial/transaction risks; watch the company’s conference call and financing details. Positive Sentiment: Cantor Fitzgerald raised its price target to $26 and kept an "overweight" rating — another bullish signal from sell‑side coverage. Article Positive Sentiment: TD Cowen initiated coverage with a "buy" rating and $30 target, adding momentum to the bullish analyst narrative. Article Positive Sentiment: Other firms (Needham to $20; JMP to $27) also lifted targets/ratings today, broadening analyst upside expectations. Needham JMP Positive Sentiment: Wedbush raised Q3 and FY2025 EPS estimates and maintains an Outperform rating, supporting expectations for improved near‑term profitability. Article Positive Sentiment: Strategic acquisition of Astria (navenibart) adds a Phase‑3, long‑acting injectable for HAE that could materially expand BioCryst’s product set and long‑term revenue runway; company expects accretion and continued non‑GAAP profitability. Press release Neutral Sentiment: BioCryst hosted an M&A call and posted transcripts/slides — useful for diligence on deal terms, timelines (close expected Q1 2026) and clinical milestones (Phase‑3 readout early 2027). Call transcript Negative Sentiment: Initial market reaction was negative: shares gapped down on the deal announcement while Astria stock jumped — investors cited dilution, near‑term financing and integration risk. Market reaction Negative Sentiment: Transaction includes a debt commitment (up to $550M from Blackstone) and stock consideration — increases leverage/dilution risk that could pressure the share price if financing terms or execution disappoint. Deal details What to watch: the investor conference call/webcast, deal close and financing details, and navenibart’s Phase‑3 ALPHA‑ORBIT readout timeframe (early 2027). These will drive whether the market rewards the strategic rationale or focuses on near‑term dilution and execution risk. Posted 6h agoAI Generated. May Contain Errors. BCRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $26.00 at Cantor FitzgeraldOctober 15 at 10:39 AM | marketbeat.comBioCryst To Buy Astria: A Calculated Gamble That Is Not Without RiskOctober 15 at 9:56 AM | seekingalpha.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated at TD CowenOctober 15 at 8:49 AM | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $20.00 Price Target at Needham & Company LLCOctober 15 at 8:24 AM | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $27.00 Price Target at JMP SecuritiesOctober 15 at 8:24 AM | marketbeat.comWedbush Issues Optimistic Outlook for BCRX EarningsOctober 15 at 7:16 AM | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 1-Year Low - Time to Sell?October 15 at 6:31 AM | marketbeat.comBioCryst To Acquire Astria Therapeutics In $700M DealOctober 14 at 9:27 PM | msn.comAstria Therapeutics stock soars after BioCryst acquisition announcement, BioCryst fallsOctober 14 at 4:26 PM | ca.investing.comBioCryst deepens rare diseases focus with $700 million deal for AstriaOctober 14 at 4:26 PM | msn.comBioCryst to buy Astria Therapeutics for $13 per shareOctober 14 at 4:26 PM | msn.comStrategic Acquisition of Astria Therapeutics by BioCryst Pharmaceuticals Highlights Potential of Navenibart for HAE ProphylaxisOctober 14 at 3:31 PM | tipranks.comBioCryst Pharmaceuticals, Inc. (BCRX) M&A Call TranscriptOctober 14 at 2:02 PM | seekingalpha.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - Here's What HappenedOctober 14 at 1:18 PM | marketbeat.comBioCryst Pharmaceuticals, Inc. (BCRX) Astria Therapeutics, Inc. - M&A Call - SlideshowOctober 14 at 12:01 PM | seekingalpha.comBayforest Capital Ltd Makes New $840,000 Investment in BioCryst Pharmaceuticals, Inc. $BCRXOctober 14 at 7:38 AM | marketbeat.comBioCryst to buy Astria Therapeutics in $700 million dealOctober 14 at 7:35 AM | reuters.comBioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio with Navenibart in $920 Million DealOctober 14 at 7:31 AM | quiverquant.comQBioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth ProfileOctober 14 at 7:00 AM | globenewswire.comWeiss Ratings Reiterates "Sell (D-)" Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)October 9, 2025 | marketbeat.comBioCryst Pharmaceuticals (BCRX) Valuation in Focus Following Latest Pipeline and Business UpdatesOctober 9, 2025 | finance.yahoo.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Zacks ResearchOctober 8, 2025 | marketbeat.comBioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US MarketOctober 4, 2025 | msn.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.2% - Here's WhyOctober 1, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given "In-Line" Rating at Evercore ISIOctober 1, 2025 | marketbeat.comBioCryst Sells European ORLADEYO Business for $250MOctober 1, 2025 | tipranks.comBioCryst Completes Sale of European ORLADEYO® (berotralstat) BusinessOctober 1, 2025 | globenewswire.comBioCryst: Blue Light Special In Small Cap Biotech AisleSeptember 29, 2025 | seekingalpha.com37,800 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Purchased by Strs OhioSeptember 24, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. $BCRX Shares Purchased by Assenagon Asset Management S.A.September 22, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Voya Investment Management LLCSeptember 20, 2025 | marketbeat.comDoliver Advisors LP Acquires 200,000 Shares of BioCryst Pharmaceuticals, Inc. $BCRXSeptember 15, 2025 | marketbeat.comAcadian Asset Management LLC Increases Stake in BioCryst Pharmaceuticals, Inc. $BCRXSeptember 15, 2025 | marketbeat.comMillennium Management LLC Has $28.60 Million Position in BioCryst Pharmaceuticals, Inc. $BCRXSeptember 14, 2025 | marketbeat.comAQR Capital Management LLC Purchases 362,175 Shares of BioCryst Pharmaceuticals, Inc. $BCRXSeptember 13, 2025 | marketbeat.comExome Asset Management LLC Takes $454,000 Position in BioCryst Pharmaceuticals, Inc. $BCRXSeptember 11, 2025 | marketbeat.comParkman Healthcare Partners LLC Buys 783,681 Shares of BioCryst Pharmaceuticals, Inc. $BCRXSeptember 8, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 7, 2025 | marketbeat.comBoothbay Fund Management LLC Sells 60,412 Shares of BioCryst Pharmaceuticals, Inc. $BCRXSeptember 6, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Graham Capital Management L.P.September 6, 2025 | marketbeat.comTrexquant Investment LP Reduces Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRXSeptember 6, 2025 | marketbeat.comNorthern Trust Corp Has $14.66 Million Holdings in BioCryst Pharmaceuticals, Inc. $BCRXSeptember 6, 2025 | marketbeat.comBioCryst Pharmaceuticals Stock (BCRX) Opinions on Q2 Revenue Surge and Conference InsightsSeptember 5, 2025 | quiverquant.comQBioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comBioCryst Pharmaceuticals, Inc. $BCRX Stake Boosted by Ieq Capital LLCSeptember 5, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Alkeon Capital Management LLCSeptember 4, 2025 | marketbeat.comPanagora Asset Management Inc. Has $3.97 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRXSeptember 4, 2025 | marketbeat.comPDT Partners LLC Raises Holdings in BioCryst Pharmaceuticals, Inc. $BCRXSeptember 3, 2025 | marketbeat.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 | globenewswire.com Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.590.72▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼298▲BCRX Articles Average Week Get the Latest News and Ratings for BCRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for BioCryst Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ALKS News Today LGND News Today FOLD News Today CLDX News Today MNKD News Today NVAX News Today OPK News Today DVAX News Today ZBIO News Today INVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.